Drugging RAS: Know the enemy
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS is the dominant oncogene in PDAC and is altered in more than 90% of tumors, with G12D, G12V, and G12R substitutions being most frequently observed (3, 4).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [3]
In the citing paper
“KRAS is the most frequently mutated oncogene, accounting for approximately 85% of all RAS mutations in 20–25% of all cancers [8–10].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [9]
In the citing paper
“It is difficult to achieve effective competition like protein kinase inhibitors [18, 19].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [19]
In the citing paper
“On the one hand, the affinity of KRAS and GTP is at the pM level, while the concentration of GTP in cells is up to 0.5 μM.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [19]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Cited by
Items 101–200 of 406
Hawash, M. (2019) · Drug Research · doi:10.1055/a-0898-7347 · Cited by 48
“On the other hand, GDP analogs are works by inhibiting the Ras signaling, since the irreversible covalent bond is formed no further activation of cascade [32, 34].”
BackgroundKRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
Kang, Y. W., Lee, J. E., Jung, K. H., Son, M. K., Shin, S., Kim, S., Fang, Z., YAN, H. H., Park, J. H., Han, B., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.013 · Cited by 45
PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling
Nawrotek, A., Benabdi, S., Niyomchon, S., Kryszke, M.-H., Ginestier, C., Cañeque, T., Tepshi, L., Mariani, A., St.Onge, R. P., Giaever, G. N., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0228-3 · Cited by 46
Kattan, W. E., Liu, J., Montufar‐Solis, D., Hong, L., Barathi, B. B., van der Hoeven, R., Zhou, Y., & Hancock, J. F. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114126118 · Cited by 47
Klomp, J. E., Lee, Y. S., Goodwin, C. M., Papke, B., Klomp, J. A., Waters, A. M., Stalnecker, C. A., DeLiberty, J. M., Drizyte‐Miller, K., Yang, R. Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110060 · Cited by 49
“Therefore, indirect approaches remain the best strategies for targeting the majority of KRAS mutant PDAC (Papke and Der, 2017).”
Self-citationSmall molecular inhibitors for KRAS-mutant cancers
Wu, X., Song, W., Cheng, C., Liu, Z., Li, X., Cui, Y., Gao, Y., & Li, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223433 · Cited by 47
Disrupted molecular glue complex drives RAS inhibitor resistance
Sang, B., Ye, L. F., Fu, Z., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Hu, F., Washington, A., Rodriguez, D. J., Vides, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.031 · Cited by 53
“We evaluated paired cell-free DNA (cfDNA) and/or tissue specimens from 40 patients with KRAS mutant NSCLC (17), CRC (15), melanoma (4), or other cancers (4), treated with daraxonrasib as part of the phase 1/1b clinical trial NCT05379985.”
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“KRAS is the most frequently mutated RAS family member (75% of RAS mutations), including high incidence of mutations in lung [4], colon [5], and pancreatic cancers [6], three of the top four causes of cancer-related death [2,7,8].”
BackgroundPannexin 1 drives efficient epithelial repair after tissue injury
Lucas, C. D., Medina, C. B., Bruton, F. A., Dorward, D. A., Raymond, M. H., Tufan, T., Etchegaray, J. I., Barron, B. J., Oremek, M. E. M., Arandjelovic, S., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm4032 · Cited by 44
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
Xie, C., Li, Y., Li, L.-L., Fan, X.-X., Wang, Y.-W., Wei, C.-L., Liu, L., Leung, E. L.-H., & Yao, X.-J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00823 · Cited by 40
“However, there is still no direct and effective drug for clinical use (Jancik et al., 2010; Gysin et al., 2011; Vasan et al., 2014; Papke and Der, 2017).”
BackgroundRegulation of large and small G proteins by ubiquitination
Dohlman, H. G., & Campbell, S. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.011068 · Cited by 41
Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor
Buyanova, M. Y., Cai, S., Cooper, J. K., Rhodes, C. A., Salim, H., Sahni, A., Upadhyaya, P., Yang, R., Sarkar, A., Li, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01130 · Cited by 41
GSK-3 as a novel prognostic indicator in leukemia
Ruvolo, P. P. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.05.001 · Cited by 39
“GSK3 mediated degradation of the Cyclin Dependent Kinase Inhibitor (CDKI) p27Kip1 was necessary for cell proliferation and survival of the MLL cells (Wang et al., 2008; Patel and Woodgett, 2008).”
BackgroundA new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1
Park, S. W., Nhieu, J., Persaud, S. D., Miller, M. C., Xia, Y., Lin, Y.-W., Lin, Y., Kagechika, H., Mayo, K. H., & Wei, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47354-7 · Cited by 46
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth
Vidimar, V., Beilhartz, G. L., Park, M., Biancucci, M., Kieffer, M. B., Gius, D. R., Melnyk, R. A., & Satchell, K. J. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000312117 · Cited by 44
Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators
Qiu, Y., Wang, Y., Chai, Z., Ni, D., Li, X., Pu, J., Chen, J., Zhang, J., Lu, S., Lv, C., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.014 · Cited by 40
Chen, P. B., Fiaux, P. C., Zhang, K., Li, B., Kubo, N., Jiang, S., Hu, R., Rooholfada, E., Wu, S., Wang, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111630 · Cited by 36
“…are frequently found in the majority of CRC (Cancer Genome Atlas Network, 2012) and are known to drive cancer proliferation by activating Wnt/ β -catenin and Ras-Raf-MEK-ERK (MAPK/ERK) signaling pathways, respectively (Fearon and Vogelstein, 1990; Papke and Der, 2017; Pylayeva-Gupta et al., 2011).”
Structure, signaling and the drug discovery of the Ras oncogene protein
Han, C. W., Jeong, M. S., & Jang, S. B. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.7.062 · Cited by 47
Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma
Phelps, M., Yang, H., Patel, S. H., Rahman, M. M., McFadden, G., & Chen, E. Y. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.09.001 · Cited by 38
“In fact, many common cancer oncogenes are undruggable by modern therapeutic approaches.(2,3) Developing therapies to target these oncogenic drivers remains one of the primary goals of current cancer research.”
BackgroundTang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01049-w · Cited by 42
Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS
Abbott, J. R., Patel, P. A., Howes, J. E., Akan, D. T., Kennedy, J. P., Burns, M. C., Browning, C. F., Sun, Q., Rossanese, O. W., Phan, J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00296 · Cited by 39
Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS
Zhao, Q., Fujimiya, R., Kubo, S., Marshall, C. B., Ikura, M., Shimada, I., & Nishida, N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108074 · Cited by 39
Zhang, H., Ni, D., Fan, J., Li, M.-Y., Zhang, J., Chen, H., Nussinov, R., & Lu, S. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00591 · Cited by 37
RAS Mutations Are Not Created Equal
Hobbs, G. A., & Der, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0406 · Cited by 35
Self-citationKRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 40
“These observations are based on the KRAS/p53 immune profile, which is characterized by an inflammatory response [21,53].”
BackgroundMethodWaters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 39
“Although at least five approaches, spanning over three decades, have been investigated to target KRAS, no clinically evaluated targeted therapies have been approved (Papke and Der, 2017; Ryan and Corcoran, 2018), which has led to the dubious distinction of KRAS being termed “undruggable” (Cox et al.”
BackgroundSelf-citationDivergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V. R., Campbell, S. L., Takeuchi, K., Senda, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707439 · Cited by 37
“Oncogenic RAS Specific Inhibitors Although RAS has been considered “undruggable” (Gysin et al., 2011; Samatar and Poulikakos, 2014; Stephen et al., 2014; Papke and Der, 2017; Welsch et al., 2017), recent discoveries identified covalent inhibitors that target Cys12 which is the reactive cysteine within the K-RAS G12C o…”
BackgroundFerrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33
“Most KRAS -mutant cancers depend on sustained expression and signaling of KRAS , thus making it a high-priority therapeutic target (Papke and Der, 2017; Stephen et al., 2014).”
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 36
Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses
Broyde, J., Simpson, D. R., Murray, D., Paull, E., Chu, B., Tagore, S., Jones, S. J., Griffin, A. T., Giorgi, F. M., Lachmann, A., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0652-7 · Cited by 33
Garrigou, M., Sauvagnat, B., Duggal, R., Boo, N., Gopal, P., Johnston, J. M., Partridge, A. W., Sawyer, T. K., Biswas, K., & Boyer, N. C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00154 · Cited by 36
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1)
Tuladhar, A., & Rein, K. S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00489 · Cited by 34
Sheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 31
Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods
Kulkarni, A. M., Kumar, V., Parate, S., Lee, G., Yoon, S., & Lee, K. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031309 · Cited by 33
“Indirect approaches include: (1) inhibiting proteins such as farnesyltransferase or PDEδ that promote the association of RAS with plasma membrane; (2) targeting proteins involved in RAS downstream signaling; (3) inhibiting synthetic lethal interaction partners for mutant RAS and (4) targeting processes that are RAS re…”
BackgroundMethodInfluentialEvaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Long, S.-A., Amparo, A. M., Goodhart, G., Ahmad, S. A., & Waters, A. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402128 · Cited by 31
“While KRAS can signal through many key effector pathways, the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) and the PI3K-Akt-mTOR (PI3K) pathways are two of the best studied due to their role in tumorigenesis (6).”
BackgroundKlein, C. H., Truxius, D. C., Vogel, H. A., Harizanova, J., Murarka, S., Martín‐Gago, P., & Bastiaens, P. I. H. (2018) · International Journal of Cancer · doi:10.1002/ijc.31859 · Cited by 32
“In previous studies, we investigated the applicability of theses inhibitors on human pancreatic cancer cell lines since the majority (90%) of pancreatic tumors harbor oncogenic KRas mutations.(3,13) All three inhibitor classes reduced cell proliferation of KRas-dependent human pancreatic ductal adenocarcinoma cells (h…”
BackgroundMechanism of activation and the rewired network: New drug design concepts
Nussinov, R., Zhang, M., Maloney, R., Tsai, C., Yavuz, B. R., Tunçbağ, N., & Jang, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21863 · Cited by 31
Luo, G., Wang, B., Hou, Q., & Wu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01729 · Cited by 30
Covalent hits and where to find them
Lucas, S. C. C., Blackwell, J. H., Hewitt, S. H., Semple, H., Whitehurst, B. C., & Xu, H. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.01.003 · Cited by 31
“1) [6 – 8].”
KRAS regulation by small non-coding RNAs and SNARE proteins
Che, Y., Siprashvili, Z., Kovalski, J. R., Jiang, T., Wozniak, G. G., Elcavage, L. E., & Khavari, P. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13106-4 · Cited by 35
Dong, X.-D., Zhang, M., Cai, C.-Y., Teng, Q.-X., Wang, J.-Q., Fu, Y.-G., Cui, Q., Patel, K., Wang, D.-T., & Chen, Z.-S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.843829 · Cited by 29
“The attempts toward recognizing small-molecule inhibitors for KRAS failed over years, consequently, KRAS was considered as an undruggable target (Downward, 2003; Wang et al., 2012; Papke and Der, 2017).”
BackgroundAdvancements in CRISPR/Cas9 technology—Focusing on cancer therapeutics and beyond
Mirza, Z., & Karim, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.026 · Cited by 31
Inhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 30
“The diverse strategies of potential Ras inhibitors have been reviewed extensively in the literature (Chatani and Yang, 2020; Cox et al., 2015; Cox et al., 2014; Dang et al., 2017; Gentile et al., 2017; Gorfe and Cho, 2019; Gupta et al., 2019; Khan et al., 2020a; Liu et al., 2010; Liu et al., 2019; Lu et al., 2016a; Lu…”
BackgroundDiehl, J. N., Klomp, J. E., Snare, K. R., Hibshman, P. S., Blake, D. R., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101335 · Cited by 29
“In a complementary approach, our chemical library screen demonstrated that concurrent inhibition of other ERK MAPK components, to block compensatory ERK reactivation, synergistically enhanced the ef fi cacy of RAF inhibitors in KRAS-mutant PDAC (27).”
InfluentialSelf-citationLee, S. G., Cho, Y., Cha, P.-H., Yoon, J.-S., Ro, E. J., Jeong, W.-J., Park, J., Kim, H., Kim, T. I., Min, D. S., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0182-2 · Cited by 29
Mollinedo, F., & Gajate, C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.06.40 · Cited by 30
“PDAC is the epitome of a treatment-resistant malignancy, driven by a so far “undruggable” oncoprotein, KRAS (20,21).”
BackgroundFrom Ras to Rap and Back, a Journey of 35 Years
Bos, J. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031468 · Cited by 33
Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
Suzuki, T., Kishikawa, T., Sato, T., Takeda, N., Sugiura, Y., Seimiya, T., Sekiba, K., Ohno, M., Iwata, T., Ishibashi, R., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00326-4 · Cited by 30
Hondo, N., Kitazawa, M., Koyama, M., Nakamura, S., Tokumaru, S., Miyazaki, S., Kataoka, M., Seharada, K., & Soejima, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216264 · Cited by 33
Liu, L., Yan, X., Wu, D., Yang, Y., Li, M., Yang, S., Yang, W., Shan, Z., Gao, Y., & Jin, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0827-y · Cited by 28
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 30
Lipid Profiles of RAS Nanoclusters Regulate RAS Function
Zhou, Y., & Hancock, J. F. (2021) · Biomolecules · doi:10.3390/biom11101439 · Cited by 26
Najumudeen, A. K., Fey, S. K., Millett, L. M., Ford, C. A., Gilroy, K. L., Gündüz, N., Ridgway, R. A., Anderson, E., Strathdee, D., Clark, W. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44342-4 · Cited by 30
Mollinedo, F., & Gajate, C. (2021) · Cancers · doi:10.3390/cancers13164173 · Cited by 26
“Thus far, PDAC is considered to be the epitome of a treatment-resistant malignancy, likely driven by the thus-far “undruggable” KRAS oncoprotein [52,53].”
BackgroundMonobodies as tool biologics for accelerating target validation and druggable site discovery
Akkapeddi, P., Teng, K. W., & Koide, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00188d · Cited by 24
Khan, I., Koide, A., Zuberi, M., Ketavarapu, G., Denbaum, E., Teng, K. W., Rhett, J. M., Spencer-Smith, R., Hobbs, G. A., Camp, E. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110322 · Cited by 26
“Further, the picomolar affinity for guanine nucleotides has precluded the successful development of nucleotide competitive inhibitors, an approach effectively utilized with kinases (Hanke et al., 1996; Lopez et al., 2014; Moore et al., 2020; O’Bryan, 2019; Papke and Der, 2017; Stalnecker and Der, 2020).”
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome
Boufraqech, M., & Nilubol, N. (2019) · Cancers · doi:10.3390/cancers11121988 · Cited by 27
“The missense mutations affect the GTP-binding domain at exon 2 (codons 12 and 13) and at exon 3 (codon 61) result in a constitutive activation of the MAPK signaling pathway as the protein is locked in a GTP-bound form [34,35].”
BackgroundTargeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 28
“Another indirect approach focuses on the downstream inhibition of KRAS activity [68].”
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 25
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA
Papke, B., Azam, S. H., Feng, A. Y., Gutierrez-Ford, C., Huggins, H., Pallan, P. S., Van Swearingen, A. E. D., Egli, M., Cox, A. D., Der, C. J., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00165 · Cited by 22
Self-citationTan, L., Cho, K.-J., Neupane, P., Capon, R. J., & Hancock, J. F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003907 · Cited by 23
“Inhibitors of the various components of the RAS spatial organizing systems may, however, have merit (5, 18, 19).”
BackgroundSmall Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses
Akan, D. T., Howes, J. E., Sai, J., Arnold, A. L., Beesetty, Y., Phan, J., Olejniczak, E. T., Waterson, A. G., & Fesik, S. W. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00869 · Cited by 22
Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
Huynh, M. V., Parsonage, D., Forshaw, T. E., Chirasani, V. R., Hobbs, G. A., Wu, H., Lee, J., Furdui, C. M., Poole, L. B., & Campbell, S. L. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102186 · Cited by 25
Recent advances in the biology and therapy of medullary thyroid carcinoma
Nelkin, B. D. (2017) · F1000Research · doi:10.12688/f1000research.12645.1 · Cited by 21
TRPML1 and RAS-driven cancers – exploring a link with great therapeutic potential
Jung, J., & Venkatachalam, K. (2019) · Channels · doi:10.1080/19336950.2019.1666457 · Cited by 21
“The paucity of success has even prompted the notion that RAS proteins might be “undruggable” [12,13,15].”
BackgroundSuppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor
Ricciardiello, F., Bergamaschi, L., Vitto, H. D., Yang, G., Zhang, T., Palorini, R., & Chiaradonna, F. (2021) · Cells · doi:10.3390/cells10020431 · Cited by 23
“Nevertheless, such targeting of mutant KRAS does not seem totally efficient yet, requiring the parallel inhibition of other targets as a resolved strategy [16,34].”
BackgroundRal Signals through a MAP4 Kinase-p38 MAP Kinase Cascade in C. elegans Cell Fate Patterning
Shin, H., Kaplan, R. E. W., Duong, T., Fakieh, R. A., & Reiner, D. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.011 · Cited by 22
Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
Badheeb, M. A., Abdelrahim, A., Esmail, A., Umoru, G., Abboud, K., Al-Najjar, E., Rasheed, G. O., Alkhulaifawi, M., Abudayyeh, A., & Abdelrahim, M. (2022) · Current Oncology · doi:10.3390/curroncol29110686 · Cited by 23
Xiao, X., Feng, J., Ma, J., Xia, X., Liu, X., Zhang, J., Ding, C., Pang, X., & Zhang, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01724 · Cited by 23
A brief history of RAS and the RAS Initiative
McCormick, F. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.003 · Cited by 22
Li, Y.-C., Lytle, N. K., Gammon, S. T., Wang, L., Hayes, T. K., Sutton, M. N., Bast, R. C., Der, C. J., Piwnica-Worms, D. R., McCormick, F. P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000848117 · Cited by 21
Self-citationTargeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells
Nishikawa, G., Kawada, K., Hanada, K., Maekawa, H., Itatani, Y., Miyoshi, H., Taketo, M. M., & Obama, K. (2022) · Cells · doi:10.3390/cells11203273 · Cited by 20
Choi, J., Shin, J. H., Kim, T. K., Kim, K., Kim, J.-Y., Jeon, E., Park, J., Han, Y. D., Kim, K., Sim, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216904 · Cited by 21
Karaboga, H., Huang, W., Srivastava, S., Widmann, S., Addanki, S., Gamage, K. T., Mazhar, Z., Ebalunode, J. O., Briggs, J. M., Gustafsson, J.-Α., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00546 · Cited by 21
Epigenetic Mechanisms beyond Tumour–Stroma Crosstalk
Gagliano, T., & Brancolini, C. (2021) · Cancers · doi:10.3390/cancers13040914 · Cited by 19
“Kras mutations occur in more than 90% of PC cases [61]; constitutive activation of KrasG12D drives unrestrained proliferation and boosts survival of cancer cells [62], thus several strategies have been developed in order to inhibit the KRAS signalling pathway [63].”
BackgroundXu, Z., Duan, F., Lu, H., Dragh, M. A. K., Xia, Y., Liang, H., & Hong, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1215-4 · Cited by 20
Nikitidis, G., Carlsson, A. C., Karlsson, S., Campbell, A. D., Cook, C., Dai, K., Emtenäs, H., Jonson, A. C., Leek, H., Malmgren, M., et al. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00179 · Cited by 19
Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?
Xiao, H., Wang, G., Zhao, M., Wen, S., Ouyang, L., & Sun, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115104 · Cited by 20
Prediction of KRASG12C inhibitors using conjoint fingerprint and machine learning-based QSAR models
Srisongkram, T., Khamtang, P., & Weerapreeyakul, N. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108466 · Cited by 24
Arafeh, R., Flores, K., Keren‐Paz, A., Maik-Rachline, G., Gutkind, N. E., Rosenberg, S. A., Seger, R., & Samuels, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-16558-0 · Cited by 19
Activation of Rho Family GTPases by Small Molecules
Palsuledesai, C. C., Surviladze, Z., Waller, A., Miscioscia, T. F., Guo, Y., Wu, Y., Strouse, J., Romero, E., Salas, V. M., Curpan, R. F., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00038 · Cited by 18
Amphiphile-Mediated Depalmitoylation of Proteins in Living Cells
Rudd, A. K., Brea, R. J., & Devaraj, N. K. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10806 · Cited by 18
Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
Tokumaru, Y., Takabe, K., Yoshida, K., & Akao, Y. (2020) · Cancer Science · doi:10.1111/cas.14357 · Cited by 18
Relaxed initiation pausing of ribosomes drives oncogenic translation
Dong, L., Mao, Y., Zhou, A., Liu, X., Zhou, J. L., Wan, J., & Qian, S. (2021) · Science Advances · doi:10.1126/sciadv.abd6927 · Cited by 18
Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 19
Self-citationEffects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D
Hoppe, J. E., Wagner, B. D., Harris, J. K., Rowe, S. M., Heltshe, S. L., DeBoer, E. M., & Sagel, S. D. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.03.012 · Cited by 21
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
Moerland, J. A., Zhang, D., Reich, L. A., Carapellucci, S., Lockwood, B., Leal, A. S., Krieger-Burke, T., Aleiwi, B., Ellsworth, E. L., & Liby, K. T. (2020) · Scientific Reports · doi:10.1038/s41598-020-79260-8 · Cited by 17
Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications
Ota, T., & Komiyama, M. (2020) · Interventional Neuroradiology · doi:10.1177/1591019920901931 · Cited by 16
“There is an opinion that cells with the mutated KRAS seem to be a therapeutic target in the treatment of bAVM.(82,83) On the other hand, Priemer et al.”
BackgroundLoftis, A. R., Santos, M. S., Truex, N. L., Biancucci, M., Satchell, K. J. F., & Pentelute, B. L. (2020) · ChemBioChem · doi:10.1002/cbic.202000201 · Cited by 16
Lowegard, A. U., Frenkel, M. S., Jou, J., Ojewole, A. A., Holt, G. T., & Donald, B. R. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007447 · Cited by 17
“As described in the Section entitled 70 “Computational redesign of the c-Raf-RBD:KRas protein-protein interface,” KRas is an 71 important cancer target that has historically been considered “undruggable” [48].”
Li, Y., Xiao, J., Zhang, T., Zheng, Y., & Jin, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897548 · Cited by 20
Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling
Garrido, C. M., Henkels, K. M., Rehl, K. M., Hong, L., Zhou, Y., Gutterman, J. U., & Cho, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-65882-5 · Cited by 16
Zhang, Z., Wang, X., Ye, J., Liu, H., Fang, J., Zhang, M., Li, Y., Huang, J., Zhang, D., Wang, J., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00426 · Cited by 15
Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
Dai, M., Jahanzaib, R., Liao, Y., Yao, F., Li, J., Teng, X., Chen, K., & Cheng, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1074538 · Cited by 17
Markov State Models Reconcile Conformational Plasticity of GTPase with Its Substrate Binding Event
Dandekar, B. R., Ahalawat, N., Sinha, S., & Mondal, J. (2023) · JACS Au · doi:10.1021/jacsau.3c00151 · Cited by 17
“9 The most common oncogenic mutations are observed in the “P-loop” region, residues 12, 13, and 61.”
Filho, R. S. D. O., de Oliveira, D. A., Nisimoto, M. Y. S. M., & Marti, L. C. (2023) · Cancers · doi:10.3390/cancers15245751 · Cited by 18
Lucas, S. C. C., Milbradt, A. G., Blackwell, J. H., Bonomo, S., Brierley, A., Cassar, D. J., Freeman, J., Hadfield, T. E., Morrill, L. A., Riemens, R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00781 · Cited by 15
RAS GTPase signalling to alternative effector pathways
Singh, S., & Smith, M. J. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200506 · Cited by 17
Kumar, S. U., Balasundaram, A., Hephzibah Cathryn, R., Varghese, R. P., Ramamoorthy, S., Ramanathan, G., Younes, S. N., Zayed, H., & Doss, C. G. P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105701 · Cited by 16
Samad, A., Khurshid, B., Mahmood, A., Rehman, A. U., Khalid, A., Abdalla, A. N., Algarni, A. S., & Wadood, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192298 · Cited by 15
“In the beginning, many indirect strategies were employed to block the oncogenic activity of the RAS family, including targeting PDE d to curb RAS or targeting the downstream effector (Papke & Der, 2017).”
Method
Metadata
- Authors
- Papke, B., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Der, Channing J.
- Venue
- Science
- Published
- 2017-03-17
- Volume
- 355
- Issue
- 6330
- Pages
- 1158-1163
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2597182072
- Cited by
- 399
- References
- 51
- Citations by year
- 2026: 25 · 2025: 37 · 2024: 45 · 2023: 30 · 2022: 46 · 2021: 52 · 2020: 48 · 2019: 51 · 2018: 45 · 2017: 20
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense (W81XWH-15-1-0611)
- National Cancer Institute (CA042978, CA175747, CA199235, CA203657)
- Pancreatic Cancer Action Network
- Lustgarten Foundation
- Deutsche Forschungsgemeinschaft (PA 3051/1-1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, anticancer drug development, Ras signaling
- MeSH terms
- Antineoplastic Agents, Cell Membrane, Enzyme Inhibitors, Humans, Mutation, Neoplasms, Drug Design, ras Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.